Q-omics provides the consensus-scored TUBA3FP profile across patient tissues and cancer cell-line models. TUBA3FP expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TUBA3FP is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, TUBA3FP RNA expression shows 16,610 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, HNSC, and TGCT as cancer lineages where TUBA3FP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUBA3FP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUBA3FP survival associations across molecular data types. TUBA3FP RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUBA3FP RNA expression–survival associations across cancer types. High TUBA3FP expression shows unfavorable associations in KIRC and UVM, but favorable associations in LUAD, PAAD, OV and BLCA. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for TUBA3FP RNA expression.
This table summarizes TUBA3FP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TUBA3FP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUBA3FP shows lower tumor expression in KICH, KIRC, LUAD, COAD and BRCA and higher tumor expression in HNSC. The HNSC box plot shows higher TUBA3FP RNA expression in tumor versus normal tissue (log2 FC = +0.289, t-test p < 0.001).
This table shows molecular features associated with TUBA3FP in patient tissues and cancer cell lines. In patient samples, TUBA3FP shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
